TWST - Tesla Crispr add most bang to ARK Innvoation ETF in Q4; Zoom Compugen are biggest drags

Familiar names topped ARK Investment Management's actively-managed ETFs last quarter, while work-from-home stocks pulled down performance as enthusiasm for recovery stocks arrived with vaccine approvals.And in her note about Q4 performance, ARK CEO Cathie Wood said it looks like cyclical sectors are catching up.The flagship, diverse ARK Innovation ETF ([[ARKK]], -1.1%) saw net asset value rise 37.44% in Q4, with market price up 37.55%, compared with a 12.15% rise in the S&P 500 ([[SP500]], +0.1%) and a 13.96% gain for the MSCI World Net Index ([[URTH]], -0.1%).Tesla ([[TSLA]], -0.1%) added 605 basis points to ARKK's performance, the most of any component, followed by Crispr Therapeutics ([[CRSP]], -2%) at 407 bps and Roku ([[ROKU]], -1.3%), which added 404.Zoom Video ([[ZM]], -0.8%) was ARKK's worst performer in the quarter, at -52 bps. Compugen ([[CGEN]], -2%) took away 45 basis points and LendingTree ([[TREE]], -0.4%) followed at -38.The ARK Genomic Revolution ETF ([[ARKG]], -2.2%) NAV rose 47.71% in Q4, with market price rising 47.61%,

For further details see:

Tesla, Crispr add most bang to ARK Innvoation ETF in Q4; Zoom, Compugen are biggest drags